Background-The precise function of angiotensin II type 2 receptor (AT 2 -R) in the mammalian heart in vivo is unknown.
A ngiotensin II (Ang II), a key regulator of cardiovascular homeostasis, binds to 2 distinct receptor isoforms, the angiotensin II type 1 receptor (AT 1 -R) and the angiotensin II type 2 receptor (AT 2 -R). 1,2 AT 1 -R has a pivotal role in the development and progression of cardiac hypertrophy. Blockade of the AT 1 -R results in regression of left ventricular hypertrophy (LVH) and improves survival in various experimental models of pressure and volume overload. 2 Moreover, the Losartan Intervention For Endpoint Reduction Study (LIFE) showed that losartan, an AT 1 -R antagonist, ameliorates LVH beyond bloodpressure reduction and, consequently, reduces cardiovascular morbidity and mortality in patients with hypertension. 3 In contrast to AT 1 -R, AT 2 -R is expressed at low levels in the normal heart; however, it is upregulated in pathophysiological conditions, including LVH. 4 -6 Several lines of evidence support the concept that AT 1 -Rmediated classic Ang II effects are counterbalanced by simultaneous activation of the AT 2 -R. 6 In agreement with this counterregulatory hypothesis, in vitro studies have shown that stimulation of the AT 2 -R exerts an antigrowth effect in various cell types, including vascular smooth muscle cells, 7 endothelial cells, 8 and cardiomyocytes. 9 Moreover, AT 2 -R blockade amplified new cardiac protein synthesis in response to Ang II ex vivo in hypertrophied hearts. 10 However, Senbonmatsu et al 11 recently reported that pressure overload failed to induce LVH in AT 2 -Rknockout mice, suggesting an obligatory requirement for AT 2 -R in the hypertrophic response. Thus, controversy exists about the precise function of AT 2 -R in the adult mammalian heart.
The aim of the present study was to examine the functional role of AT 2 -R in cardiac pressure overload. We infused Ang II in the presence and absence of PD123319, a selective AT 2 -R antagonist, [12] [13] [14] [15] to characterize the effect of AT 2 -R blockade on Ang II-induced hypertension, LV function, LVH, and changes in LV expression of peptide growth factors, growth-inhibiting substances, and angiogenic factors in vivo.
Methods

Experimental Design
Male Sprague-Dawley rats (nϭ132; body weight, 313Ϯ3 g) from the Center for Experimental Animals at the University of Oulu were used. Vehicle, Ang II (33 g · kg Ϫ1 · h Ϫ1 , Sigma), 16 PD123319 (1.25 mg · kg Ϫ1 · h Ϫ1 ) 12-14 (a gift from Dr Joan A. Keiser, Parke-Davies Co), losartan (400 g · kg Ϫ1 · h Ϫ1 ) 12-14 (a gift from Dr Ronald D. Smith, DuPont Merck Pharmaceutical Co), or Ang IIϩPD123319 or Ang IIϩlosartan was administered via subcutaneously implanted osmotic minipumps (Alzet). PD123319 has high affinity (K i Ͼ12 nmol/L) for the AT 2 -R but a low affinity (K i Ͼ100 mol/L) for the AT 1 -R. Therefore, administration of PD123319 at a dose of 1.25 mg · kg Ϫ1 · h Ϫ1 , yielding a plasma concentration of Ϸ500 nmol/L, would result in an effective AT 2 -R blockade without affecting the AT 1 -R. 15 After 12 or 72 hours of treatment, LVs were weighed, frozen in liquid nitrogen, and stored at Ϫ80°C, as described previously. 16 
Monitoring of Blood Pressure and Heart Rate
Telemetric monitoring of mean arterial pressure (MAP) and heart rate was performed as described previously. 16 Echocardiography LV function and chamber dimensions were assessed by transthoracic echocardiography using the Acuson Ultrasound System (Sequoia 512) and a 15-MHz linear transducer (15L8) as described previously. 17
Isolation of Cytoplasmic RNA and Northern Blot Analysis
Total RNA was isolated from LV tissue by the guanidine thiocyanate CsCl method, and 20-g samples of RNA were transferred to nylon membranes (Osmonics) for Northern blot analysis as described previously. 16 Full-length rat atrial natriuretic peptide (ANP) cDNA probe (a gift from Dr Peter Davies, Queen's University, Kingston, Canada), a 390-bp rat B-type natriuretic peptide (BNP) cDNA probe, and an 18S cDNA probe were prepared as previously reported. 16 cDNA probes for rat ␣-actin and myosin isoforms were made by reverse transcription-polymerase chain reaction (RT-PCR) and ligated to dT-tailed pCR2.1 vector by use of a TA Cloning Kit (Invitrogen). Sequencing with ABI PRISM 310 Genetic Analyzer (Applied Biosystems) confirmed that the probes correspond to bases 2950 to 3184 of rat skeletal ␣-actin (GenBank Accession Number v01218), 289 to 447 of rat cardiac ␣-actin (x00306), 5794 to 5923 of rat ␤-myosin heavy chain (␤-MHC) (x15939), and 5830 to 5921 of rat ␣-myosin heavy chain (␣-MHC) (x15938). cDNA probes were labeled, and the membranes were hybridized, washed, and quantified as previously described. 16 
Real-Time Quantitative RT-PCR Analysis
The cDNA was synthesized from 0.5 g total RNA derived from LV tissue (First-Strand cDNA Synthesis Kit, Amersham). Rat c-fos, endothelin-1 (ET-1), insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF), fibroblast growth factor-1 and -2 (FGF-1 and -2), transforming growth factor-␤ 1 (TGF-␤ 1 ), and 18S RNA levels were measured by real-time quantitative RT-PCR analysis using TaqMan chemistry on an ABI Prism 7700 Sequence Detection System (Applied Biosystems) as described previously. 18 The sequences of the forward and reverse primers and probes for RNA detection are presented in the Table.
Radioimmunoassay for ANP and BNP
Immunoreactive ANP (ir-ANP) and ir-BNP levels were measured by radioimmunoassays from extracted LV tissue samples as described previously. 16 
Statistical Analysis
Results are expressed as meanϮSEM. The data were analyzed with 1-way ANOVA followed by Bonferroni post hoc test. The hemody-namic variables were analyzed with repeated-measures ANOVA. Differences at the level of PϽ0.05 were considered statistically significant.
Results
Hemodynamic Parameters
MAP, measured by telemetry, was similar in all groups before the beginning of the infusions ( Figure 1A ). Ang II infusion produced a rapid increase in MAP, reaching maximum values at 14 hours, after which it remained elevated until the end of the experiment. In agreement with previous studies, [12] [13] [14] [15] PD123319 infusion alone had no effect on MAP; moreover, it did not modify Ang II-induced increase in blood pressure ( Figure 1A) , showing that AT 2 -R is not involved in the regulation of blood pressure. As described previously, the increase in MAP by Ang II was associated with a significant decrease in heart rate, 16 remaining unaffected by PD123319 ( Figure 1B ). Echocardiographic measurements showed that LV ejection fraction ( Figure 1C ) and LV fractional shortening ( Figure 1D ) were similar in all groups, suggesting that LV function was preserved in Ang II-induced hypertension.
LVH and Contractile Protein Gene Expression
LV weight to body weight (LVW/BW) ratio increased by 9% at 12 hours (PϽ0.01) and 16% at 72 hours (PϽ0.001; Figure  1E ) in Ang II-infused rats compared with controls. Administration of AT 2 -R antagonist alone had no effect on LVW/BW ratio and did not significantly change the Ang II-induced increase in LVW/BW ratio ( Figure 1E ). Echocardiographic measurements revealed similar changes in LV mean wall thickness ( Figure 1F ). Furthermore, upregulation of skeletal ␣-actin and ␤-MHC mRNA levels in the LV was similar in the Ang II and Ang IIϩPD123319-infused groups at 72 hours ( Figure 2 , C and D). Moreover, ␣-MHC mRNA levels decreased similarly in Ang II-infused rats with or without AT 2 -R blockade ( Figure 2B ). PD123319 treatment alone did not influence the gene expression of ␣-actin and MHC isoforms ( Figure 2, A and B ).
LV c-fos Gene Expression
Upregulation of c-fos gene is a hallmark of cardiac hypertrophy induced by mechanical stretch or growth-promoting factors. 19 Ang II treatment caused a transient increase (5.1fold; PϽ0.01 versus sham) in c-fos mRNA at 12 hours ( Figure 3A ). In the presence of AT 2 -R antagonist, Ang II induced a more marked and sustained increase in c-fos mRNA levels, the increase being 10-fold at 12 hours (PϽ0.01 versus sham; PϽ0.05 versus Ang II alone; Figure 3A ) and 6-fold at 72 hours (PϽ0.01 versus sham; PϽ0.05 versus Ang II alone; Figure 3B ). PD123319 treatment alone had no effect on LV c-fos gene expression.
LV Gene Expression of ET-1 and Peptide Growth Factors
The increase in c-fos expression in the presence of AT 2 -R blocker could be mediated by increased expression of growth-promoting factors such as ET-1 and peptide growth factors. 19 Ang II alone had no effect on ET-1 mRNA levels; however, it upregulated ET-1 gene expression in the presence of PD123319 by 2.2-fold (PϽ0.05) and 3-fold (PϽ0.001) at 12 and 72 hours, respectively ( Figure 4, A and B ). IGF-1 mRNA levels were elevated 1.5-fold (PϽ0.05) at 72 hours only in the Ang IIϩPD123319 group ( Figure 4C ). Moreover, Ang II reduced VEGF and FGF-1 mRNA levels by 49% and 46% (PϽ0.01, Figure 4 , D and E), respectively, only in the presence of AT 2 -R blockade. In contrast to these changes, FGF-2 mRNA levels increased similarly during Ang II infusion alone and in combination with AT 2 -R antagonist ( Figure 4F ), whereas TGF-␤ 1 gene expression was not modified by the treatments (data not shown). PD123319 infusion alone had no effect on the LV gene expression of ET-1 or peptide growth factors.
LV Expression of ANP and BNP
Because AT 2 -R blockade resulted in an augmented expression of growth-promoting factors in response to Ang II without an increase in LV mass, we measured expression of natriuretic peptides, which exert antihypertrophic effect in vivo. 20, 21 Ang II infusion resulted in 2.9-fold (PϽ0.001) and 10.5-fold (PϽ0.001) increases in LV ANP mRNA levels at 12 and 72 hours, respectively ( Figure 5, A and B) . Interestingly, PD123319 significantly augmented the Ang II-induced increase in ANP mRNA levels at 12 hours (PϽ0.01, Figure  5A ). In addition, LV ir-ANP levels increased 2.6-fold in Ang II-infused rats compared with those in control animals at 72 hours (PϽ0.01), and combined administration of Ang II and PD123319 further increased ir-ANP levels (PϽ0.05 versus Ang II; Figure 5D ). Moreover, PD123319 increased ir-BNP levels in Ang II-infused animals by 23% (PϽ0.05) and 36% (PϽ0.05) at 12 and 72 hours ( Figure 6 , C and D), respectively; meanwhile, the transient Ang II-induced increase in BNP mRNA levels was not modified during AT 2 -R blockade ( Figure 6, A and B) . Administration of PD123319 alone had no effect on ANP and BNP mRNA or ir-ANP and ir-BNP levels ( Figures 5 and 6 ).
Blockade of Ang II-Induced Hypertrophic Effects by Losartan
AT 1 -R blockade by losartan completely abolished Ang IIinduced changes in the cardiac gene expression at both time points ( Figure 2, A and B, and Figure 7 ). When given alone, losartan did not modify mRNA levels. Losartan also abolished the Ang II-induced increase in LVW/BW ratio (2.47Ϯ0.09 versus 2.12Ϯ0.03, PϽ0.001) and hemodynamics (data not shown).
Primer and Probe Sequences Used for Real-Time Quantitative RT-PCR Analysis
Gene Sequence
5Ј-GATCCGCAGACGTGTAAATGTTC-3Ј
Reverse
5Ј-TTAACTCAAGCTGCCTCGCC-3Ј
Probe 5Ј-Fam-TGCAAAAACACAGACTCGCGTTGCA-Tamra-3Ј
FGF-1
Forward
5Ј-ATGGCACCGTGGATGGG-3Ј
5Ј-TTTCCGCACTGAGCTGCAG-3Ј
Probe 5Ј-Fam-AGGGACAGGAGCGACCAGCACATTC-Tamra-3Ј
FGF-2
5Ј-CCCGGCCACTTCAAGGAT-3Ј
5Ј-GATGCGCAGGAAGAAGCC-3Ј
Probe 5Ј-Fam-CCAAGCGGCTCTACTGCAAGAACGG-Tamra-3Ј
18S
5Ј-TGGTTGCAAAGCTGAAACTTAAAG-3Ј
5Ј-AGTCAAATTAAGCCGCAGGC-3Ј
Probe 5Ј-Vic-CCTGGTGGTGCCCTTCCGTCA-Tamra-3Ј 
Discussion
The precise role of AT 2 -R in the development of LVH is controversial. 22, 23 Previously, in vitro studies have shown that AT 2 -R stimulation inhibits the growth of various cell types, including cardiomyocytes, 9 by counteracting AT 1 -R signaling. However, in 2 different lines of AT 2 -R knockout mice, either pressure overload failed to generate LVH 11, 24 or the increases in ventricular mass and myocyte cross-sectional area were comparable to those in nontransgenic littermates. 25, 26 Our results show that in vivo Ang II-induced hypertrophic process is regulated by AT 2 -R, because PD123319, a selective AT 2 -R antagonist, 12 markedly upregulated the gene expression of various hypertrophy-inducing (eg, ET-1, IGF-1) and growth-inhibiting (eg, ANP) factors in the rat heart. AT 2 -R is expressed at very high levels in the heart of the developing fetus, and it may play a significant role during embryogenesis. 27 In the present experiments, to avoid the possible embryogenic effects of the lack of AT 2 -R, we inhibited AT 2 -R in adult hearts by means of a pharmacological approach. Telemetry and echocardiographic measurements documented that AT 2 -R blockade with PD123319 had no effect on Ang II-induced pressor response or LV function, respectively. Moreover, Ang II-induced increase in LVW/BW ratio, an index of LVH, and elevation of skeletal ␣-actin and ␤-MHC mRNA levels were not altered by PD123319. These observations suggest that AT 2 -R blockade has no impact on vascular tone or LV function and it does not trigger additional increase in cardiac mass.
Although LVH was not affected during AT 2 -R blockade in Ang II-induced hypertension, the LV gene expression of c-fos, a hallmark of ventricular hypertrophy, was markedly upregulated. Moreover, Ang II was able to induce a prominent increase in ET-1 mRNA levels only in the presence of AT 2 -R blockade. ET-1 induces cardiac hypertrophy, myocardial cellular injury, and ventricular arrhythmias, and in-creased ET-1 synthesis contributes to the progression of chronic heart failure. 28 Long-term ET A receptor blockade significantly ameliorates LV dysfunction, prevents histological and electrical ventricular remodeling, suppresses ventricular arrhythmias, and therefore greatly improves survival in various models of experimental heart failure. 29, 30 In addition to ET-1, combined administration of Ang II and PD123319 significantly elevated the mRNA level of IGF-1, a peptide growth factor involved in cardiomyocyte proliferation and differentiation. 31 It was demonstrated previously that Ang II-induced arteriolar growth was blunted by PD123319 in the hypertrophied heart. 14 The marked downregulation of the pivotal angiogenic factors, VEGF 32 and FGF-1, 33 by Ang IIϩPD123319 treatment may offer an explanation for the impairment of AT 2 -R-regulated angiogenesis. In contrast to the above-mentioned changes, FGF-2 mRNA levels increased similarly, whereas TGF-␤ 1 gene expression was not changed during Ang II infusion alone or in combination with PD123319. These data demonstrate that although the degree of Ang II-induced pressure overload was comparable in the presence and absence of AT 2 -R blockade, the gene expression of peptide growth factors was differentially regulated in the heart, suggesting that AT 2 -R has a specific role in the cardiac hypertrophic process in vivo.
Notably, there was an apparent discrepancy between the marked upregulation of growth-promoting factors and the lack of effect on ventricular mass during AT 2 -R blockade in Ang II-induced hypertension. Such dissociation could be explained by the counterbalancing effect of increased synthesis of substances with antihypertrophic properties. 20, 21 Indeed, levels of ANP mRNA, ir-ANP, and ir-BNP were significantly higher in Ang IIϩPD123319-treated animals, suggesting that a new equilibrium has been established between the production of growth-promoting and growth-inhibiting factors. Importantly, plasma ET-1 and BNP levels have been demonstrated to be powerful predictors of mortality in patients with heart failure characterized by mechanical dysfunction or arrhythmic instability. 34, 35 Thus, increased production of these factors in the presence of AT 2 -R blockade may be associated with a poor prognosis in the long term.
The present observations may have important clinical implications for the treatment of human heart failure. The expression level of AT 2 -R is much higher in human hearts than in rodent hearts; moreover, the ratio of AT 2 -R to AT 1 -R increases in failing human hearts. 4 -6 Thus, AT 2 -R-related beneficial effects could be further activated under these pathophysiological conditions by drugs with simultaneous AT 1 -R antagonist and AT 2 -R agonist properties, and therefore, they may be more favorable than AT 1 -R blockers alone. Of note, losartan, a selective AT 1 -R antagonist, was not superior to captopril, an ACE inhibitor, in improving survival in elderly heart-failure patients. 36 In summary, the present study provides evidence that AT 2 -R plays a functional role in the cardiac hypertrophic process in vivo by counterbalancing AT 1 -R-mediated growth effects. Our results show that AT 2 -R blockade selectively regulates the gene expression of c-fos, ET-1, IGF-1, FGF-1, VEGF, and ANP in the LV during the development of myocardial hypertrophy. Taken together with previous findings, the changes in gene transcription observed during AT 2 -R blockade might aggravate LVH and lead to cardiac dysfunction and arrhythmic instability in the long run. These data support the hypothesis that stimulation of the AT 2 -R has a beneficial effect during pressure overload.
